Patents

1. Bharate SB, Kumar A, Manda S, Joshi P, Bharate SS, Wani A, Sharma S, Vishwakarma RA. Alkylidene Phosphonate esters as P-glycoprotein inducers. WO2016063297A1, 3010DEL2014. Granted in EP - EP3209671 (Feb 2019).

2. Bharate SB, Kumar A, Bharate JB, Joshi P, Wani A, Mudududdla R, Sharma R, Vishwakarma RA. Polyalkylated acyl and benzoyl-phloroglucinols as potent P-glycoprotein inducers. WO2016063296A1; 3004DEL2014. Granted in US - US10202326B2 (Feb 2019)

3. Bharate SB, Kumar A, Manda S, Joshi P, Bharate SS, Vishwakarma RA. N-Substituted beta-carbolinium compounds as potent P-glycoprotein inducers. WO2016063303A1, 3002DEL2014. Granted - US10072009 (Sept 2018)

4. Vishwakarma RA, Bharate SB, Bhushan S, Mondhe DM, Jain SK, Meena S, Guru SK, Pathania AS, Kumar S, Behl A, Mintoo MJ, Bharate SS, Joshi P. Cyclin-dependent kinase inhibition by 5,7-dihydroxy-8-(3-hydroxy-1-methylpiperidin-4-yl)-2-methyl-4H-chromen-4-one analogs. WO2014170914A1, US20160052915, EP2986605, CA2908084, IN2013DE01142. Granted in US, EP - US9932327B2 (April 2018). EP2986605 (Nov 2017)

5. Jain SK, Sidiq T, Meena S, Khajuria A, Vishwakarma RA, Bharate SB. Preparation of tetrahydro-2H-pyrano[3,2-c]isochromene-6-one analogs for the treatment of inflammatory disorders. WO2014188440A1, 1565DEL2013. Granted in US, EP- US9777014B2 (October 2017) EP 3004116 (January 2018)

6. Vishwakarma R, Jain SK, Bharate SB, Dar AH, Khajuria A, Meena S, Bhola SK, Qazi AK, Hussain A, Sidiq T, Uma Shaanker R, Ravikanth G, Vasudeva R, Patel MK, Ganeshaiah KN. New chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders. IN 2013DE01077A; WO2014167580A1. Granted in US, EP- US9776989 B2 (October 2017), EP 2984078 (Oct 2017)

7. Vishwakarma RA, Bharate SB, Kumar A, Singh B, Kumar A, Bhushan S, Hamid A, Joshi P, Guru SK, Kumar S, Hussain A, Qazi AK, Bharate SS, Sharma P, Saxena AK, Mondhe DM, Mahajan G, Wani Z. 10-Substituted colchicinoids as potent anticancer agents. WO2016059650A1, 2929DEL2014. Granted in US, EP- US9868695 (January 2018), EP3207026 (Nov 2018)

8. Vishwakarma RA, Kumar A, Khan IA, Bharate SB, Joshi P, Singh S, Satti N. A pharmaceutical composition for the treatment of multi-drug resistant infections. WO2016067309A1; 3077DEL2014. Granted in EP - EP15807704.0

9. Vishwakarma RA, Bharate SB, Bhushan S, Yadav RR, Guru SK, Joshi P. 6-Aryl-4-phenylaminoquinazolines as phosphoinositide 3 kinase inhibitors and their preparation, pharmaceutical compositions and use in the treatment of cancer. WO2015128873A1, 0554DEL2014. Granted in EP - EP3110801B1 (January 2019)

10. Singh IP, Bhutani KK, Mitra D, Chauthe SK, Bharate SB, Sabde S. Novel dimeric phloroglucinol compounds as anti-HIV and microbicidal agents. 1055/DEL/2009. Granted (India) - Patent no. 289013

11. Bharate SB, Sharma R, Joshi P, Vishwakarma RA, Chaudhuri B. Furanochalcones and furanoflavones as inhibitors of CYP1A1, CYP1A2 and CYP1B1 for cancer chemoprevention. IN201611027579, WO2018029710

Granted - EP3497097 (June 2019)

12. Thompson CM, Bharate SB. Benzothiazole-based pyridinium compounds. US20150259336A1. Granted in US - US9255091B2 (February 2016).

13. Bharate SB, Bhushan S, Mohammed S, Guru SK, Bharate SS, Kumar V, Mahajan G, Javed MM, Mondhe DM, Vishwakarma RA. Fused pyrimidines as isoform-selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof. WO2017090058A1, 3818DEL2015.

14. Bharate SS, Kumar V, Singh R, Rani S, Gupta M, Kumar A, Bharate SB, Vishwakarma RA. Sustained release formulations of Crocus sativus. IN201711036084, WO2019077621A1 , Licensed to industry

15. Bharate SS, Singh R, Gupta M, Singh B, Katare AK, Kumar A, Bharate SB, Vishwakarma RA. Gastroretentive sustained release formulations of Bergenia ciliata. IN201711036683; WO2019077620A1

16. Bharate SS, Kumar V, Gupta M, Gandhi S, Kumar A, Bharate SB, Vishwakarma RA. Sustained release formulations of Dysoxylum binectariferum. IN201811014818, WO2019202610A1

17. Bharate SS, Kumar V, Mintoo MJ, Mondhe DM, Bharate SB, Vishwakarma RA. Novel oral formulation of anticancer compound with improved efficacy. IN201811026240; WO202012498A1